The material class addressed in the following application scenarios is a pre-blended aqueous film coating powder for pharmaceutical dosage forms. The dry system typically contains a film-forming polymer, plasticizer, anti-tack agent, opacifier, and process aid. The polymer fraction varies by function: hypromellose or polyvinyl alcohol for immediate-release and moisture-protective coats, methacrylic acid copolymer for enteric coats, ethylcellulose or polyacrylate for sustained-release coats, and PLGA or polylactide for injectable depot microparticles. Because these powders are dispersed rather than fully dissolved, hydration, screen filtration, and spray-atomization behavior directly affect film integrity and batch-to-batch reproducibility. The sections below address only downstream manufacturing routes for which pharmacopoeial acceptance procedures, regulatory clauses, and production-scale equipment envelopes are documented.

In a 48-inch perforated side-vented pan coater processing 400–600 kg of tablet cores, immediate-release film coating is applied as an aqueous dispersion at 10–20% w/w solids; the target weight gain is 2.0–4.0 wt% of the uncoated core. The coating powder is dispersed in purified water using a high-shear mixer at 800–1,500 rpm for 45–60 min and passed through a 60–100 mesh screen before spraying. Tablets entering the coater should meet USP <1216> friability ≤0.5% and exhibit hardness of 8–12 kp to prevent edge chipping and film separation under pan rotation. For hypromellose-based systems, inlet air temperature is maintained at 60–75 °C with bed temperature 40–50 °C, atomizing air at 2.0–3.5 bar, spray rate 8–20 g/min/kg, pan speed 4–12 rpm, and exhaust air flow 1,200–2,000 cfm. Inlet air dew point is controlled below 10 °C to prevent surface tack during the first spray phase. Below 2.0 wt% weight gain, edge coverage and colour uniformity can fail visual inspection; above 4.5 wt%, disintegration under USP <701> can exceed the 15-min limit for immediate-release tablets. Process controls are documented under 21 CFR 211.110, and finished tablets are tested by USP <711> for release. The terminal product is an immediate-release film-coated tablet for oral administration; the coat does not materially modify release rate but provides taste masking, dust control, and dose identification.

What Limits Aqueous Film Coating of Granules in High-Shear and Fluid-Bed Lines?

Aqueous film coating of granules for taste masking shifts the failure mode away from tablet edge-chipping and toward fluid-bed agglomeration and partial film coverage on high-surface-area substrates. The coating powder is commonly an ethylcellulose or basic methacrylate copolymer system dispersed at 10–15% w/w solids and applied to extruded-spheronized pellets of 500–1,000 µm or high-shear granules of 200–500 µm; functional weight gain for taste masking typically falls at 10–25 wt% depending on API bitterness and granule porosity. In top-spray fluid-bed equipment with a 60–120 kg production bowl, inlet air is set to 50–65 °C, product temperature 35–42 °C, spray rate 5–12 g/min/kg, atomization air 2.5–3.5 bar, and air volume adjusted to maintain fluidization without slugging. The main process limit is droplet size relative to granule diameter; droplet sizes above 20 µm at low bed humidity create twinning and agglomeration, while overly fine atomization below 10 µm generates spray-dried polymer fines that do not coalesce on the substrate. If API bitterness persists and weight gain exceeds 20 wt%, release delay can become measurable under USP <711>, requiring revalidation of dissolution acceptance. Residual solvent and elemental impurity limits follow ICH Q3C(R9) and ICH Q3D. Terminal product types include taste-masked granules for reconstitution, sachets, orally disintegrating tablets, and coated pellets filled into hard capsules.

When Enteric Protection Is Required for Acid-Labile Cores

Enteric protection imposes a measurable release cutoff rather than a cosmetic film requirement. The coating powder must contain a gastric-resistant methacrylic acid copolymer, typically methacrylic acid copolymer Type A or Type B, plasticized with triethyl citrate at 10–20% of dry polymer; the powder is dispersed at 15–20% w/w solids in water and applied after an isolating subcoat to prevent interfacial incompatibility. The addition ratio for tablet cores is 8–12 wt% weight gain, while pellets require 15–30 wt% because of higher surface area and curvature. In a side-vented pan coater, inlet air is maintained at 55–70 °C, bed temperature 35–45 °C, spray rate 6–14 g/min/kg, atomizing air 2.5–3.5 bar, and pan speed 6–12 rpm. The critical process conflict is acid-stage failure when weight gain falls below 6 wt% on tablets: cracks and edge defects allow >10% drug release in 0.1 N HCl after 2 h, violating USP <711> enteric test limits. Above 14 wt% weight gain, buffer-stage release at pH 6.8 can be delayed beyond 45 min under the same USP <711> procedure, causing batch rejection. Curing after spraying at 40–50 °C for 30–60 min is required to complete film coalescence; uncured methacrylic acid copolymer films show pH-dependent permeability drift. Parallel testing in EU submissions may use Ph. Eur. 2.9.3 dissolution. The terminal product is an enteric-coated tablet or enteric-coated multiparticulate pellet filled into capsules for oral administration.

For tablet cores containing deliquescent or hydrolytically labile actives, the film coating must reduce moisture ingress without delaying disintegration beyond the immediate-release window. A polyvinyl alcohol-based film coating powder applied at 3.0–5.0 wt% weight gain in a perforated pan coater reduces water vapor transmission when the film is fully coalesced; water vapor transmission rate is measured by ASTM F1249 on free films cast from the same dispersion, with acceptance set relative to the uncoated core moisture uptake under USP <671> container permeation protocols. The dispersion is prepared at 12–18% w/w solids and applied with inlet air 60–70 °C, bed temperature 42–48 °C, atomizing air 2.5–3.5 bar, spray rate 6–12 g/min/kg, and pan speed 6–12 rpm. Below 3.0 wt% weight gain, the moisture barrier remains incomplete and edge seams show localized water uptake; above 5.5 wt%, disintegration under USP <701> can exceed 15 min for immediate-release tablets, creating a narrow processing window. The downstream process includes post-coating drying at 40 °C for 10–15 min and immediate transfer to low-relative-humidity packaging; open storage at RH >60% before packaging can reduce barrier performance through film plasticization. Terminal product types are moisture-protected immediate-release tablets and coated pellets intended for pack formats with desiccant or high-barrier blisters.

Sustained-Release Pellet Coating in Wurster Fluid-Bed Equipment

Wurster bottom-spray coating of pellets converts a pre-blended ethylcellulose or polyacrylate powder into a release-controlling membrane after curing, but the process window narrows when the spray droplet size approaches the pellet diameter. Pellets from extrusion-spheronization are classified to 500–800 µm or 800–1,000 µm before loading into a Wurster insert; the coating powder is dispersed at 10–15% w/w solids, and weight gain is set from 5–30 wt% depending on target release duration: 5–10 wt% for 8–12 h, 15–20 wt% for 12–24 h, and 25–30 wt% for extended release beyond 24 h. In a production Wurster unit with a 46-inch insert, inlet air is held at 45–60 °C, product temperature 28–35 °C, spray rate 4–10 g/min/kg, atomizing air 2.5–3.5 bar, and air volume sufficient to maintain a pressure differential of 100–200 mm H2O across the distributor. Agglomeration occurs when product temperature exceeds 40 °C or spray rate rises above 12 g/min/kg, producing film fusion between pellets and yield loss through retained on-sieve fractions. After coating, curing at 60 °C for 2–24 h is required for ethylcellulose films to reach stable coalescence; under-cured membranes show burst release in the first 2 h under USP <711> dissolution testing. Release acceptance follows USP <711> or Ph. Eur. 2.9.3 with multiple time points. Terminal product types are sustained-release pellets in capsules, sustained-release tablets, and multiparticulate sachets.

For Gelatin/HPMC Capsule Shells, Coating and Band Sealing as a Single Process

Capsule shell coating and band sealing is a closure-integrity operation rather than a cosmetic colour step, though the same aqueous powder dispersion is often used at lower atomizing air pressure than tablet coating. The coating powder is dispersed at 10–15% w/w solids and applied to filled, joined capsules in a dedicated capsule coating pan or banding machine at 30–40 °C drying air; weight gain is controlled to 3–6 mg/capsule, and banding solution solids are 12–20% w/w. Process limits arise from shell softening: gelatin capsules exposed to bed temperature above 35–40 °C or excessive water flux lose dimensional integrity, while HPMC shells tolerate slightly higher temperature but show slower drying. Atomizing air is reduced to 1.5–2.5 bar to avoid shell surface erosion. The finished capsules must meet USP <701> disintegration and USP <711> dissolution limits, and in-process weight uniformity is checked under 21 CFR 211.110. Terminal product type is coated hard capsules with tamper-evident band seal.

In injectable depot applications, an oral hypromellose or polyvinyl alcohol film coating powder is not directly transferable unless the polymer is a biodegradable PLGA or polylactide grade meeting parenteral requirements. The coating or matrix polymer is dissolved in dichloromethane at 5–20% w/w solids, and the drug-to-polymer ratio is typically set from 1:1 to 1:5, producing a polymer fraction of 10–40 wt% in the final microparticle. The downstream process is solid-in-oil-in-water solvent evaporation: the drug-polymer organic phase is emulsified into a continuous aqueous phase containing 0.5–2.0% w/v polyvinyl alcohol using a rotor-stator high-shear mixer at 5,000–15,000 rpm; the resulting emulsion is stirred under reduced pressure to remove dichloromethane, then the microparticles are collected, washed, and lyophilized. Compliance testing includes USP <85> bacterial endotoxin, USP <87> in vitro biological reactivity, USP <88> Class VI in vivo biological reactivity, ISO 10993-5 cytotoxicity, and limits consistent with ICH Q3D and ICH Q3C for residual dichloromethane. Published data for standard oral film coating powders repurposed to this injectable configuration is limited; the numerical ranges in this paragraph derive from PLGA microparticle literature rather than direct transfer of hypromellose-based oral coats. Terminal product type is a lyophilized injectable microparticle depot suspension for intramuscular or subcutaneous administration after reconstitution.